Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

Launched by ALCON RESEARCH · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new eye drop called Reformulated PG324 to see if it can safely and effectively lower eye pressure in people who have open-angle glaucoma or ocular hypertension. These conditions cause increased pressure inside the eye, which can damage vision over time if not treated. The goal of the study is to find out if this new treatment can help reduce that pressure and protect eyesight.

People who might be eligible to join the study are adults between 65 and 74 years old who have been diagnosed with open-angle glaucoma or ocular hypertension in both eyes. Participants should have reasonably good vision (at least 20/100 in the eye being studied) and specific eye pressure levels measured without any eye pressure-lowering medications recently. Those currently using more than two eye pressure medications or with very high eye pressure (over 36 mmHg) will not qualify. If you join, you can expect to stop using certain eye medications before starting the study and follow the study’s schedule for eye exams and treatment with the new eye drops. This study is not yet open for enrollment but aims to help find better treatments for eye pressure problems in the future.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Diagnosis of open-angle glaucoma or ocular hypertension in both eyes;
• • Unmedicated intraocular pressure measurements in the study eye as specified in the protocol;
• • Corrected distance visual acuity equal to or better than 20/100 in the study eye.
• Key Exclusion Criteria:
• • Current use of more than 2 ocular hypotensive medications within 30 days;
• • Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening;
• • Use of topical ocular medication of any kind within 5 days of Screening or throughout the study with the exception of ocular hypotensive medications (must be washed out).